1. Zhao, Wennan, Wang, Xue, Han, Lifeng, Chen, Xin, Zhang, Youcai. 2024. SLC13A3 is a major effector downstream of activated β-catenin in liver cancer pathogenesis. In Nature communications, 15, 7522. doi:10.1038/s41467-024-51860-2. https://pubmed.ncbi.nlm.nih.gov/39215042/
2. Hussain, Syeda Iqra, Muhammad, Nazif, Shah, Salah Ud Din, Wasif, Naveed, Khan, Saadullah. 2023. Structural and functional implications of SLC13A3 and SLC9A6 mutations: an in silico approach to understanding intellectual disability. In BMC neurology, 23, 353. doi:10.1186/s12883-023-03397-y. https://pubmed.ncbi.nlm.nih.gov/37794328/
3. Markovich, Daniel. . Sodium-sulfate/carboxylate cotransporters (SLC13). In Current topics in membranes, 70, 239-56. doi:10.1016/B978-0-12-394316-3.00007-7. https://pubmed.ncbi.nlm.nih.gov/23177988/
4. Wong, Kristen N, Botto, Lorenzo D, He, Miao, Vanderver, Adeline L, Bonkowsky, Joshua L. 2023. Novel SLC13A3 Variants and Cases of Acute Reversible Leukoencephalopathy and α-Ketoglutarate Accumulation and Literature Review. In Neurology. Genetics, 9, e200101. doi:10.1212/NXG.0000000000200101. https://pubmed.ncbi.nlm.nih.gov/38235040/
5. Kang, Qingyun, Yang, Liming, Liao, Hongmei, Liao, Caishi, Wu, Liwen. 2021. Case Report: Compound Heterozygous Variants of SLC13A3 Identified in a Chinese Patient With Acute Reversible Leukoencephalopathy and α-Ketoglutarate Accumulation. In Frontiers in pediatrics, 9, 801719. doi:10.3389/fped.2021.801719. https://pubmed.ncbi.nlm.nih.gov/34966709/
智鼠故事 
